Article Text
Statistics from Altmetric.com
Q In patients with high risk atherothrombosis, is long term treatment with clopidogrel plus aspirin more effective than aspirin alone for reducing cardiovascular (CV) events?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Neurology ★★★★★★☆ Cardiology ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management, and Avoidance [CHARISMA]).
Allocation:
concealed.*
Blinding:
blinded {clinicians, patients, data collectors, outcome assessors, data analysts, and data safety and monitoring committee}†.*
Follow up period:
median 28 months.
Setting:
768 sites in 32 countries.
Patients:
15 603 patients ⩾45 years of age (median age 64 y, 70% men, 80% white) who had multiple atherothrombotic risk factors (type 1 or 2 diabetes, diabetic nephropathy, ankle brachial index <0.9, asymptomatic carotid stenosis ⩾70% of luminal diameter, ⩾1 carotid plaque, systolic blood pressure ⩾150 …
Linked Articles
- Glossary